Eli Lilly and Company (NYSE:LLY) Shares Down 1.2% – Time to Sell?

Shares of Eli Lilly and Company (NYSE:LLY) fell 1.2% on Monday . The company traded as low as $1,042.92 and last traded at $1,045.08. 3,397,473 shares changed hands during mid-day trading, a decline of 1% from the average session volume of 3,444,488 shares. The stock had previously closed at $1,058.18.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4B to add in‑vivo CAR‑T/circular RNA capabilities — a strategic entry into next‑generation cell and genetic medicines that analysts and the stock market treated as a growth catalyst. Lilly to buy Orna Therapeutics for up to $2.4 billion
• Positive Sentiment: Lilly expanded its Innovent Biologics collaboration (up to ~$8.5B in potential payments), extending oncology/immunology reach and global development capacity — another long‑term revenue opportunity outside its core GLP‑1 franchise. Eli Lilly Enters $8.5 Billion Strategic Collaboration with Innovent Biologics and Acquires Orna Therapeutics
• Positive Sentiment: Analysts now expect robust 2026 growth — reports project >21% revenue growth and >40% adjusted EPS growth — and at least one major shop raised its price target, supporting a constructive long‑term outlook. Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth in 2026
• Neutral Sentiment: Coverage pieces compare Lilly vs. Novo Nordisk and dig into relative value/market share — useful context for portfolio positioning but not an immediate catalyst. Novo Nordisk vs. Eli Lilly: What’s the Better Long-Term Investment?
• Neutral Sentiment: Analyses of international revenue trends and investor attention provide background on which regions and products could offset U.S. pricing headwinds. Unlocking Lilly (LLY) International Revenues
• Negative Sentiment: Concentration risk: >60% of recent revenue came from GLP‑1 drugs (Mounjaro, Zepbound), exposing LLY to pricing pressure, competition and potential demand changes — a key reason some traders are taking profits. Over 60% of Eli Lilly’s Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?
• Negative Sentiment: Investor actions and macro headlines — including a reported stake trim by Bristol Gate Capital and ongoing discussion of U.S. price declines for GLP‑1s — add near‑term volatility risk. Bristol Gate Capital Partners Trims Eli Lilly Stake

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LLY shares. Zacks Research cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a research note on Monday. Daiwa Securities Group set a $1,230.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Finally, Jefferies Financial Group increased their target price on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,207.29.

Eli Lilly and Company Stock Down 1.2%

The firm has a market capitalization of $988.00 billion, a P/E ratio of 45.54, a P/E/G ratio of 0.91 and a beta of 0.39. The company has a fifty day simple moving average of $1,052.25 and a 200 day simple moving average of $899.78. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 26.14%.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IPG Investment Advisors LLC raised its stake in shares of Eli Lilly and Company by 232.5% in the fourth quarter. IPG Investment Advisors LLC now owns 1,586 shares of the company’s stock worth $1,704,000 after purchasing an additional 1,109 shares during the last quarter. Connecticut Capital Management Group LLC bought a new stake in Eli Lilly and Company in the 4th quarter worth about $1,111,000. Smith Chas P & Associates PA Cpas raised its position in Eli Lilly and Company by 133.5% in the 4th quarter. Smith Chas P & Associates PA Cpas now owns 1,214 shares of the company’s stock worth $1,305,000 after buying an additional 694 shares during the last quarter. Barry Investment Advisors LLC bought a new position in Eli Lilly and Company during the 4th quarter valued at about $325,000. Finally, Severin Investments LLC boosted its holdings in shares of Eli Lilly and Company by 3.2% during the 4th quarter. Severin Investments LLC now owns 702 shares of the company’s stock valued at $755,000 after acquiring an additional 22 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.